Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063828 · ClinicalTrials.gov registry record · NA
Reducing Lung Cancer-Related Anxiety (RELAX)
A NA study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT02063828: Clinical Trial NA study, sponsored by Wake Forest University Health Sciences.
NCT02063828 is a NA study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02063828, a NA study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the effects of music and different levels of device-guided breathing on anxiety and shortness of breath in lung cancer survivors.
Primary Outcome
Retention will be calculated as the number of participants who complete the final assessment divided by number randomized.
Interventions
- DEVICE Group A - Device guided breathing low dose
- DEVICE Group B - Device guided breathing high dose
- DEVICE Group C - Usual Breathing Control Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-07-30 |
| Est. Completion | 2019-12-23 |
| Phase | NA |
Why NCT02063828 stopped before completion
NCT02063828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Group A - Device guided breathing low dose is the first listed.
NCT02063828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02063828 about?
NCT02063828 is a clinical study titled "Reducing Lung Cancer-Related Anxiety (RELAX)". The purpose of this research study is to compare the effects of music and different levels of device-guided breathing on anxiety and shortness of breath in lung cancer survivors.
What is the current status of trial NCT02063828?
This trial is currently terminated. It is a NA study. The enrollment target is 46 participants. The study started on 2015-07-30. Estimated completion is 2019-12-23.
What interventions are being tested in trial NCT02063828?
The interventions under investigation include: Group A - Device guided breathing low dose (DEVICE), Group B - Device guided breathing high dose (DEVICE), Group C - Usual Breathing Control Group (DEVICE).
Who is sponsoring clinical trial NCT02063828?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02063828's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI